Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 19, 2026.

Differential TAM receptor–ligand–phospholipid interactions delimit differential TAM bioactivities

Erin D Lew, Jennifer Oh, Patrick G Burrola and 5 more

eLife · 2014 · CC BY

doi:10.7554/elife.03385

Abstract

The TAM receptor tyrosine kinases Tyro3, Axl, and Mer regulate key features of cellular physiology, yet the differential activities of the TAM ligands Gas6 and Protein S are poorly understood. We have used biochemical and genetic analyses to delineate the rules for TAM receptor–ligand engagement and find that the TAMs segregate into two groups based on ligand specificity, regulation by phosphatidylserine, and function. Tyro3 and Mer are activated by both ligands but only Gas6 activates Axl. Optimal TAM signaling requires coincident TAM ligand engagement of both its receptor and the phospholipid phosphatidylserine (PtdSer): Gas6 lacking its PtdSer-binding ‘Gla domain’ is significantly weakened as a Tyro3/Mer agonist and is inert as an Axl agonist, even though it binds to Axl with wild-type affinity. In two settings of TAM-dependent homeostatic phagocytosis, Mer plays a predominant role while Axl is dispensable, and activation of Mer by Protein S is sufficient to drive phagocytosis.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

The three receptor tyrosine kinases of the TAM family–Tyro3, Axl, and Mer—are expressed in sentinel cells of the immune system, endothelial cells of the vasculature, neurons and glia of the nervous system, and professional phagocytes of the immune, nervous, and reproductive systems. In these settings, TAM signaling regulates multiple functions but two are especially prominent. The first is the ‘homeostatic’ or silent phagocytosis of the billions of apoptotic cells (ACs) that are generated on a daily basis throughout life. The second is the inhibition of the innate immune inflammatory response in dendritic cells (DCs), macrophages, and other sentinel cells of the immune system. Deficiencies in TAM expression or activity lead to autoimmunity, blindness, and infertility. Conversely, over-expression or aberrant activation of Tyro3, Axl, or Mer (gene name Mertk) is associated with the development, progression, and metastasis of cancers. Axl in particular has been shown to mediate the resistance of solid tumors and leukemias to epidermal growth factor receptor (EGFR)-directed chemotherapeutic agents. Elevated TAM expression has also recently been implicated in increased susceptibility to infection by enveloped viruses.

The importance of TAM activity notwithstanding, the differential signaling capacity of the two soluble ligands that activate TAM receptors—Gas6 and Protein S (gene and protein names Pros1)—is incompletely understood. Gas6 is thought to function as a ligand for all three receptors, but the role of Pros1 as a ligand for one or more TAM receptors has until recently been controversial. At the same time, the unique structural features of Gas6 and Pros1—in which a C-terminal ‘SHBG domain’ binds to the Ig-like domains of TAM receptors while an N-terminal γ-carboxylated ‘Gla domain’ binds, in a Ca2+-dependent reaction, to the phospholipid phosphatidylserine (PtdSer)—have led to conflicting conclusions as to the relative importance of these two domains in receptor binding vs activation. Although Gas6 and Pros1 binding to the PtdSer-containing membranes of enveloped viruses potentiates TAM activation, and the Gla domain is thought to be required to ‘bridge’ a TAM receptor expressed on the surface of a phagocyte to the PtdSer expressed on the surface of its AC target, a preparation of recombinant mouse Gas6 that lacks the Gla domain entirely is sold commercially as a TAM activator.

Potentially distinct roles for Pros1 and Gas6 in vivo have only recently begun to be appreciated, and to date only a single genetic study of the importance of Gas6 vs Pros1 in a TAM-dependent process has been reported. This study addressed TAM signaling during the phagocytosis of photoreceptor (PR) outer segments by retinal pigment epithelial (RPE) cells, which express Mer and Tyro3 but no Axl. RPE phagocytosis of the PtdSer-displaying tips of PR outer segments requires Mer—mice, rats, and humans that carry loss-of-function mutations in the Mertk gene are blind, due to the cell-non-autonomous degeneration of nearly all PRs. This cell death results from the accumulation of toxic oxidated proteins that are generated during the course of phototransduction and are removed by phagocytosis. Retinal loss of either the mouse Gas6 or Pros1 gene alone yields a retina with a normal number of PRs, but the combined loss of Pros1 and Gas6 results in a PR degeneration phenotype that fully phenocopies the cell death seen in Mertk−/− mice. While this analysis demonstrated that Pros1 is sufficient to drive Mer-dependent phagocytosis in RPE cells, the presence of Tyro3 in these cells raised the possibility that Pros1 activation of the Mer kinase might be dependent on Pros1 binding to Tyro3.

In the current study, we have used biochemistry, receptor activation profiling, and genetic analyses of single and compound mouse mutants to establish the basic rules for TAM ligand–receptor interaction, signaling, and function. We find that Gas6 activates all three TAM receptors, but is an especially potent ligand for Axl, with which it has a unique association. In contrast, Pros1 activates Tyro3 and Mer but is inactive as an Axl agonist. Notably, we find that the Gla domains of TAM ligands are dispensable for receptor binding but are critical for optimal receptor activation, and that for Gas6 activation of Axl, this requirement is absolute. We conclude that a complete TAM signaling module is composed of a receptor, a γ-carboxylated protein ligand, and the phospholipid PtdSer, a tripartite arrangement that is unique to the TAM family. Finally, we show that Mer is the functionally predominant TAM receptor in two different settings of ‘homeostatic’ PtdSer-dependent phagocytosis in vivo–in the retina and the testes–and that Pros1 binding to and activation of Mer alone is sufficient to ensure wild-type levels of phagocytosis in these settings.

Derivation of assay tools

We first generated highly pure preparations of recombinant mouse Gas6 and Pros1. We transfected pCEP4-based expression plasmids containing cDNAs for both full-length and Gla domain-deleted (‘Gla-less’) versions of these TAM ligands into HEK293 EBNA cells and selected stable transformants. Lines expressing the highest levels of each ligand were grown in serum-free production medium supplemented with vitamin K2, required for γ-carboxylation of Gla domain glutamic acid residues. Ligands were purified to apparent homogeneity from conditioned medium, using affinity purification on a nickel-NTA resin followed by size exclusion and anion exchange chromatography (see ‘Materials and methods’).

All recombinant mouse ligands ran as single bands under reducing conditions on SDS polyacrylamide gels and eluted from an anion exchange column as a single peak suggesting that the ligands were pure (Figure 1A and data not shown). Commercially available Protein S purified from human plasma (hPros1) ran as a single predominant band under reducing conditions, together with a secondary band of lower molecular weight (Figure 1A). Size exclusion chromatography suggested that full-length Gas6 in solution is a mixture of monomers, dimers, and/or higher order multimers, whereas the Gla-less form appeared as a monomer (Figure 1—figure supplement 1). These elution profiles are consistent with earlier work on hPros1, indicating that it forms disulfide-linked multimers, and that multimerization is enhanced by apoptotic cells.

In order to have cellular assay targets in which individual TAM receptors could be expressed and their expression level normalized between cell lines, we first prepared immortalized mouse embryo fibroblast (MEF) lines from embryonic day (E)13.5 Tyro3−/−Axl−/−Mertk−/− triple mutants (‘TAM TKO’) and all three possible double mutants (e.g., Tyro3−/−Mertk−/−, or ‘TM DKO’) (; see ‘Materials and methods’). The TAM TKO MEF lines provide a baseline cell population that lacks expression of any TAM receptor and the double mutant lines isolate a single receptor. This was particularly important, since in surveys of established cell lines we were unable to identify any human, mouse, rat, hamster, or monkey immortalized line that did not express at least one endogenous TAM receptor. [Selected examples of TAM expression in cultured cells are shown in Figure 1—figure supplement 2] This suggests that all prior analyses of TAM receptor activation have been encumbered by the expression of endogenous Tyro3 and/or Axl and/or Mer.

We generated multiple clonal cell lines in the background of the TAM TKO MEFs that express HA-tagged versions of mouse Tyro3, Axl, and Mer, respectively. We then selected one clonal population from the Tyro3 and Axl sets that expressed equivalent levels of these receptors, based on detection of the HA tag (Figures 1B and 2D; see ‘Materials and methods’). Expression in these Tyro3- and Axl-expressing MEFs was not maximal among the clones we isolated but was physiological in that we did not observe receptor activation (autophosphorylation) in the absence of added ligand (Figure 2), a phenomenon frequently observed when RTKs are over-expressed. Although we were also able to isolate MEF lines expressing Mer, these lines always (for unknown reasons) expressed much lower levels of this receptor (Figure 1C and data not shown). For the Mer-expressing MEF line analyzed in this paper, we used a stable clonal line generated by expressing HA-tagged recombinant mouse Mer under the control of a TetExpress-inducible promoter (Clontech; Figure 1C). For the Tyro3- and Axl-expressing MEF lines, we used Tyro3 and Axl antibodies directed against the extracellular domains of the receptors to live label non-permeabilized cells in culture and demonstrate surface expression of the individual receptors (Figure 1B). Mer expression in clonal, Tet-inducible Mer_TAM TKO MEF lines, while detectable by western blot (Figure 1C), was too low to be detected by immunocytochemistry.

Distinct TAM receptor activation profiles for Gas6 and Pros1

We first assayed full-length recombinant mouse Gas6 and Pros1, together with purified human Pros1, for their ability to activate mouse Tyro3, Axl, and Mer. We measured activation of single receptors expressed in MEFs by monitoring their tyrosine phosphorylation 10 min after ligand addition to cells in serum-free medium, using immunoprecipitation with antibodies to the individual receptors (or their C-terminal HA tag) followed by immunoblotting with an anti-phosphotyrosine antibody (see ‘Materials and methods’). We found that both purified human and recombinant mouse Pros1 (hPros1 and rmPros1, respectively) were capable of rapidly activating Tyro3 autophosphorylation (Figure 2A–C). In our hands, purified hPros1 was more stable biochemically and often more potent than rmPros1 (Figure 2A), and we therefore used the human protein for the majority of the Pros1 experiments described below. However, both the mouse and human ligands were active (Figure 2B,C). Consistent with these observations, both mouse and human Pros1 were also recently found to be active as ligands for a chimeric receptor comprised of the mouse Tyro3 ectodomain linked to the cytoplasmic domain of the R1 chain of the interferon (IFN)-gamma (γ) receptor. (Activation of this chimera, expressed in CHO cells, was monitored by tyrosine phosphorylation of STAT1.)

Mouse Tyro3 was also strongly activated by rmGas6 (Figure 2B–D). In contrast, we found that mouse Axl could only be activated by rmGas6 (Figure 2D–F). While we detected 10 min activation of Axl at rmGas6 concentrations as low as 1 nM (Figure 2D), we could not detect Axl activation by either mouse Pros1 (Figure 2E) or human Pros1 (Figure 2F) at any concentration tested. Correspondingly, hGas6 but not mPros1 has been found to induce STAT1 phosphorylation downstream of a chimeric mAxl/γR1 receptor expressed in CHO cells.

We used similar dose–response titrations to assess the ability of Gas6 and Pros1 to activate Mer. We found that both ligands were capable of activating this receptor in Mer-expressing MEFs, but that rmGas6 was more potent than hPros1 in this assay (Figure 2G). Finally, as our Mer-expressing MEFs have much lower receptor levels than Tyro3 or Axl-expressing MEFs, we also performed the same analysis using dexamethasone-treated mouse bone marrow-derived macrophages (Dex_Mϕ). These cells have levels of Mer comparable to those of Tyro3 or Axl in the MEF cell lines and do not express any other TAM receptor (;; and data not shown). We found that both rmGas6 and hPros1/rmPros1 also function as a ligand for Mer in these cells (Figure 2H and Figure 2—figure supplement 1).

The Gas6 Gla domain is essential for optimal TAM receptor activation

Together with several components of the blood coagulation cascade, including prothrombin, Protein C, and factors VII, IX, and X, both Gas6 and Pros1 carry ‘Gla domains’—polypeptide segments of ∼45 amino acids that contain clusters of 10–12 glutamic acid residues whose gamma carbons are post-translationally carboxylated in a vitamin K-dependent reaction. This γ-carboxylation of glutamic acid is required for the Ca2+-dependent binding of Gla domains to PtdSer, which is displayed on the surface of apoptotic cells (ACs) and enveloped viruses. It is indispensible for the bioactivity of the Gla domain-containing proteins of the coagulation cascade and is a principal reason that vitamin K is an essential vitamin. The anticoagulant warfarin and related blood thinners antagonize vitamin K-dependent γ-carboxylation of Gla domains.

We first compared the ability of full-length vs Gla-less mouse Gas6 to activate Tyro3. Gla-less Gas6 is deleted for the first 115 residues of the protein, including the Gla domain, but retains all four EGF-like domains and the SHBG-like domain. We found that although both full-length and Gla-less rmGas6 were capable of activating Tyro3, the full-length protein was markedly (∼20-fold) more potent (Figure 3A). When we performed this same comparison for Axl-expressing MEFs, we observed an even stronger dependence. Full-length Gas6 was a very potent Axl ligand (Figure 3B, left 6 lanes), but the Gla-less version was incapable of activating Axl at any concentration tested (up to 750 nM; Figure 3B, right 6 lanes). We found that this stark disparity was unique to Axl. When we compared the ability of full-length and Gla-less rmGas6 to activate Mer in Mer-expressing Dex-Mϕ, we observed a pattern similar to that seen for Tyro3. Although both forms of the ligand were capable of activating Mer, full-length Gas6 was ∼20-fold more potent than its Gla-less counterpart (Figure 3C). Thus, the TAM receptors fall into two groups based on features of their ligand and PtdSer activation profiles: Tyro3 and Mer are activated by both Gas6 and Pros1, whereas Axl is activated only by Gas6; and while Gla-less Gas6 is a substantially weaker ligand for Tyro3 and Mer, it is effectively dead as a ligand for Axl.

The difference in the ability of Gla-less Gas6 to activate Axl vs Tyro3/Mer is unrelated to any difference in the intrinsic tyrosine kinase activity of the three receptors. We found that a Tyro3–Axl chimeric receptor composed of the Tyro3 extracellular domain linked to the Axl tyrosine kinase, when expressed in TAM TKO MEFs, displayed diminished activation by Gla-less Gas6 similar to that seen with Tyro3 (Figure 3A,D). This suggests that the interaction of Gla-less Gas6 to Tyro3 and Mer is distinct structurally from its interaction with Axl. Together, these results indicate that the Gas6 Gla domain is required for optimal activation of Tyro3 and Mer, and that this requirement is absolute for Axl.

The Gas6 Gla domain is dispensable for Axl binding

We asked whether the marked difference in Axl activation displayed by full-length vs Gla-less rmGas6 was reflected in a difference in Axl binding. Since there have been conflicting reports as to the relative binding affinity of full-length vs Gla-less Gas6 to Axl-Fc fusion proteins, as measured by using BIAcore sensor chips, we measured their Axl binding affinities in a more biologically relevant context; that is, to intact Axl receptor expressed on the surface of TM DKO MEFs (prepared from Tyro3−/−Mertk−/− embryos) in culture. We radio-iodinated full-length rmGas6 and then performed conventional competitive binding assays using displacement with increasing concentrations of either unlabeled full-length Gas6 or unlabeled Gla-less Gas6 (see ‘Materials and methods’).

We found that full-length and Gla-less Gas6 displayed essentially the same IC50 for Axl binding—approximately 0.7 nM in this assay (Figure 3E). Thus, the inability of Gla-less Gas6 to activate Axl is unrelated to its ability to bind the receptor; and conversely, the ability of a Gas6 variant to bind Axl is unrelated to its ability to activate the receptor. These properties suggest that a crystal structure of the Axl ectodomain bound to Gla-less Gas6 represents a ligand-occupied but inactive Axl configuration. In related work, we have found that these properties are also exceptionally important to Gas6–Axl binding and signaling in tissues in vivo, where Gas6 appears to be specifically and constitutively bound to Axl without significant activation of the receptor. Consistent with the failure of Pros1 to activate Axl in culture (Figure 2E,F), we detected no binding of Pros1 to Axl-expressing MEFs (data not shown).

Phosphatidylserine is present in MEF cultures

The importance of PtdSer for TAM ligand activity suggests that this phospholipid must be available to the purified TAM ligands that are added to MEF cultures (as in Figures 2 and 3). This is in spite of the fact that PtdSer is largely confined to the inner leaflet of the plasma membrane bilayer of non-apoptotic cells through the action of a set of P4-ATPases—so-called flippases. Consistent with this hypothesis, we found that the PtdSer-binding protein Annexin A5 antagonized Gas6 activation of Tyro3 in Tyro3_TAM TKO MEFs (Figure 4A). We therefore probed for the presence of PtdSer in MEF cultures directly. We co-incubated MEFs (grown under the same conditions we used for activation studies) with propidium iodide (PI) and the fluorescent Annexin B12 derivative pSIVA, a polarity-sensitive biosensor that fluoresces only when bound to PtdSer, and then analyzed the cells by flow cytometry. We detected significant number of pSIVA+PI− apoptotic cells and pSIVA+PI+ late apoptotic/necrotic cells in the culture medium and even a measurable number of pSIVA+PI− and pSIVA+PI+ cells in the adherent MEFs on the plate (Figure 4B). Together, these results demonstrate that there are PtdSer-displaying membranes present in the MEF cultures. It is important to note that the molecular weight of PtdSer is ∼385 g/mol, while Gas6 and Pros1 have molecular weights of ∼80,000 g/mol, and that the crystal structure of the prothrombin Gla domain bound to lyso-PtdSer contains only a single molecule of this phospholipid. Thus, a relatively low level of PtdSer can easily be in molar excess over the Gla domain-containing proteins with which it interacts. In this regard, the addition of either PtdSer-displaying enveloped viruses or PtdSer-displaying apoptotic cells has been found to markedly shift the dose–response curves for Pros1 activation of Mer and Gas6 activation of Axl/Mer to lower ligand concentrations.

Gas6 binding to Axl is calcium independent but Gas6 activation of Axl is calcium dependent

The binding of Gla domains to PtdSer is also Ca2+-dependent and can be rapidly disrupted by Ca2+-chelating agents such as EDTA. We therefore used immunocytochemistry to ask if rmGas6 binding to Axl in Axl-expressing MEFs is Ca2+-dependent. We found that it is not: binding of rmGas6 (at 25 nM) to the surface of Axl-expressing MEFs was readily observed with an anti-Gas6 antibody at 90 min after application (at 4°C), and this binding was unaffected by the inclusion of 10 mM EDTA (Figure 4C). We also detected equivalent binding of Gla-less Gas6 (Figure 4C). In control experiments, no Gas6 binding was detected in TAM TKO MEFs (Figure 4D). These results argue that the observed Gas6 binding is via SHBG domain binding to Axl and not via Gla domain binding to any PtdSer expressed by the MEFs. We then asked whether Gas6 bound to Axl in the presence of EDTA (Figure 4C, third panel) is capable of activating Axl. We found that it is not: although 10 nM rmGas6 resulted in strong Axl activation in the absence of EDTA, the inclusion of 2, 10, or 50 mM EDTA all blocked this activation (Figure 4E). These results indicate that the binding of full-length Gas6 alone, in the absence of simultaneous Ca2+-dependent binding of its Gla domain to PtdSer, is insufficient to trigger Axl activation.

Gas6 activation of Axl in vivo

We next extended these cell culture observations to an in vivo setting. We injected either full-length or Gla-less rmGas6 intravenously (IV) into Gas6−/− mice and then used immunohistochemistry to monitor the binding of these injected proteins to splenic red pulp macrophages. F4/80+ red pulp macrophages express both Axl and Mer and are normally also Gas6+. By 30 min after IV injection, we observed equally strong binding of both full-length and Gla-less rmGas6 to these cells (Figure 5A). However, this equivalent in vivo binding was not reflected in equivalent Axl activation. When we immunoprecipitated Axl from the spleen 30 min after IV injection of full-length Gas6, we observed that Axl was strongly activated (Figure 5B). In marked contrast, Axl immunoprecipitated after injection of Gla-less rmGas6 showed zero activation (Figure 5B). This was in spite of the fact that equivalent amounts of full-length and Gla-less Gas6 could be recovered from the spleen (Figure 5B). The PtdSer required for activation of Axl by full-length rmGas6 injected IV is presumably provided by both apoptotic cells and circulating PtdSer-exposing microparticles, derived from platelets, erythrocytes, leukocytes, and endothelial cells, which are abundant in the blood.

TAM signaling differences reside in the Ig-like domains of the receptors

We found that the distinct receptor–ligand activation profiles described above reflect differences that are intrinsic to the Ig-like domains of the TAM ectodomains. We compared the ability of rmGas6 and hPros1 to activate TAM receptor autophosphorylation in MEF lines expressing either full-length Tyro3 or a chimeric receptor composed of the Tyro3 extracellular domain linked to the tyrosine kinase domain of Axl (Figure 6A). This chimeric receptor was also expressed well in clonal TAM TKO MEF lines (Figure 6B and Figure 6—figure supplement 1). The activation profiles of both rmGas6 (Figure 6C) and hPros1 (Figure 6D) were similar for MEF lines expressing equivalent levels of wild-type Tyro3 or the chimeric Tyro3–Axl hybrid. We found that specificity resides within the two N-terminal Ig-like domains of the receptors, and that both of these domains are required: a hybrid receptor composed of the two Ig-like domains of Tyro3 linked to the remaining domains of Axl (Figure 6A) was, like Tyro3, potently activated by Pros1 (Figure 6D, lanes 5–8), whereas a chimera that contained only the first Ig-like domain of Tyro3 (Figure 6A) was refractory to activation by Pros1 (Figure 6D, lanes 1–4). These results indicate that the intrinsic catalytic activity of Axl and Tyro3 are stimulated to comparable levels by ligand binding—of either Gas6 or Pros1–to the Tyro3 extracellular domain.

Genetic delineation of TAM receptor–ligand interactions in the retina

We extended our in vitro observations of differential TAM interactions to two in vivo settings in which genetic analyses have shown that TAM signaling plays an essential role. The first of these is the phagocytosis of the distal tips of photoreceptor's (PR) outer segments by the retinal pigment epithelial (RPE) cells of the eye. As noted above, Mer is absolutely required for this phagocytosis. In Mertk−/− mice, a phagocytic deficiency results in the nearly complete death of PRs by 12 weeks of age. We have previously shown that Tyro3 mouse mutants, Gas6 mouse mutants, and retina-specific Pros1 mouse mutants all have a normal number of PRs at this time; but that Gas6/Pros1 double mutants display PR death and retinal degeneration that fully phenocopies the degeneration of the Mertk mutants.

These analyses demonstrate that Pros1 acts as an effective Mer activator during RPE cell phagocytosis but not that this occurs through direct binding of Pros1 to Mer. To address this question, we generated Tyro3−/−Gas6−/− double mutants. In these mice, the only TAM ligand remaining is Pros1, and the only TAM receptor through which it can bind and signal in RPE cells is Mer. As noted above, RPE cells do not express Axl, which, in addition, is only activated by Gas6 (Figure 2E,F). As described previously, PR death can be assessed quantitatively in retinal sections by measuring the radial thickness of the outer nuclear layer (ONL), which is composed exclusively of PR nuclei. In 10–12-week old wild-type (Figure 7A, first panel), Gas6−/− (Figure 7A, third panel), and Tyro3−/− retinae (Figure 7A, fourth panel), the ONL has a normal radial thickness of ∼50 μm and consists of 12–15 compact PR nuclei. In marked contrast, the Mertk−/− ONL is reduced to a thickness of only 1–4 PR nuclei (Figure 7A, second panel). (The Figure 7A panel illustrates a region of severe PR degeneration in which the ONL is only one nucleus thick.) We found that the Tyro3−/−Gas6−/− ONL is also of wild-type thickness (Figure 7A, fifth panel). Thus, Pros1–Mer signaling alone is sufficient to mediate apparently normal phagocytosis in the retina.

We also assessed the ability of hPros1 to activate Mer in a dissected RPE layer preparation in vitro. As before, we isolated the eyecup from either wild-type or Tyro3−/− adult mice and removed the cornea, lens, and retina to leave the apical surface of the RPE cell layer exposed. We then treated this surface, where Mer and Tyro3 are localized, with hPros1. We have shown previously that purified Pros1 can enhance Mer autophosphorylation in this preparation. As shown in Figure 7B (upper two panels), we demonstrate that purified Pros1 can also activate Tyro3 in this preparation and can activate Mer in both wild-type and Tyro3−/− RPE cells (Figure 7B, lower two panels). Thus, Pros1 induces Mer autophosphorylation in the RPE directly, in the absence of any other TAM receptor, and this Pros1-to-Mer activation alone is sufficient to maintain a normal number of PRs in the retina in vivo.

Genetic delineation of TAM receptor–ligand interactions in the testes

A second setting in which PtdSer-dependent TAM signaling plays an essential role is the homeostatic phagocytosis of apoptotic cells in the seminiferous tubules of the testes. This setting is distinct from retina, where RPE cells phagocytize only a portion of a living cell. In the testes, Sertoli cells must engulf and clear millions of apoptotic germ cells that are generated normally during every cycle of mammalian spermatogenesis (>108/day in a human male). Sertoli cells express all three TAM receptors and both ligands, and Tyro3/Axl/Mer triple mouse mutants are infertile due to the toxic accumulation of ACs. We used immunostaining with antibodies to activated (cleaved) caspase 3 (cCasp3; see ‘Materials and methods’) to quantify the number of ACs present in the 10–12-week seminiferous tubules across an informative set of TAM receptor and ligand mutants. We counted all activated cCasp3+ cells throughout an entire testis section and then normalized these counts to the number of tubule cross-sections present per testis section, which averaged 262.1 ± 20.6 (1 S.D.) and did not vary significantly for any of the genotypes we analyzed (data not shown).

We found that the major receptor required for Sertoli cell phagocytosis of apoptotic germ cells in the mouse testis is Mer (Figure 8A,B and Figure 8—figure supplement 1). While Tyro3−/−, Axl−/−, and Gas6−/− single mutant mice all displayed wild-type number of cCasp3+ ACs—∼0.02 cells per tubule cross-section (Figure 8A, and Figure 8—figure supplement 1)–Mertk−/− mice displayed nearly 20 times more (Figure 8B). In contrast to other tissues we have analyzed (e.g., the spleen), the number of ACs was not increased in Mertk−/−Axl−/− double knock-outs compared to Mertk−/− single knock-outs (Figure 8—figure supplement 1A,C). More tellingly, Tyro3−/−Axl−/− double knock-outs displayed wild-type number of ACs in the testes (Figure 8—figure supplement 1A,C), and this was also the case for Tyro3−/−Gas6−/− double knock-outs, in which the only possible TAM signaling axis is Pros1 to Mer (Figure 8A,B).

In contrast to the retina, we observed a significant effect of Tyro3 mutation in the presence of an existing Mertk mutation: Tyro3−/−Mertk−/− double mutants displayed substantially more ACs in the testis (∼2 cCasp3+ cells per each tubule cross-section) than did Mertk−/− single mutants (Figure 8—figure supplement 1A,C). Combining all three receptor knock-outs in Tyro3−/−Axl−/−Mertk−/− triple mutants led to a massive accumulation of ACs and cCasp3+ material that made accurate counting of ACs impossible (Figure 8—figure supplement 1A). This suggests that in the absence of Mer and Tyro3, Axl can also mediate AC phagocytosis. Finally, we examined the effect of removing all Gas6 and half the normal Pros1 throughout the mouse and found that the Prosfl/−Gas6−/− testes also contained a wild-type number of ACs (Figure 8—figure supplement 1C). Thus in both the testes and the retina, only half the normal level of only a single TAM ligand (Pros1) is sufficient to maintain an essential level of TAM-dependent phagocytosis.

All three TAM receptors are detectable by western blot in the testis (Figure 8C), and there was no significant compensatory change in Tyro3, Axl, or Mer expression in Mertk−/−, Tyro3−/−, Gas6−/−, or Tyro3−/−Gas6−/− mice (Figure 8C). We used comparative signal intensities on Licor immunoblots of lysates from testis and TAM TKO MEFs expressing HA-tagged Tyro3, Axl, and Mer (Figure 8D) to determine that the relative protein expression level of TAM receptors in the testis is Mer > Tyro3 > Axl (Figure 8E). Finally, we confirmed that the phenotypes we analyzed at 10–12 weeks were fully developed by this time. We measured the number of cCasp3+ cells in wild-type vs Tyro3−/−Mertk−/− mice at 10–12 weeks vs 9–12 months and saw that this number was the same in both the young and aged testis (Figure 8—figure supplement 1D). Together, these results indicate that Mer is the major facilitator of steady-state homeostatic phagocytosis in both the retina and the testis, and that binding and activation of this receptor by Pros1 alone at only half its normal gene dose is sufficient to maintain normal levels of phagocytosis.

TAM rules of engagement

From the above analyses, we draw seven salient conclusions with respect to TAM receptor–ligand–phospholipid interactions, which are summarized in Figure 9. First, Gas6 alone is capable of binding to and activating Tyro3, Axl, and Mer when these receptors are expressed in isolation and is especially potent as a ligand for Axl. Second, Pros1 alone is capable of binding to and activating Tyro3 and Mer but does not function as a ligand for Axl. Third, the PtdSer-binding Gla domain of Gas6, PtdSer itself, and calcium are all required for optimal receptor activation but none is required for receptor binding. Fourth, ligand binding does not translate into receptor activation: Gla-less Gas6 binds as well to Axl as does its full-length counterpart, but is dead as an activator, and full-length Gas6 binds to Axl in the presence of EDTA but does not activate. Fifth, receptor heterodimerization is not an essential feature of TAM activation, since the TAM receptors can be activated by purified single ligands when expressed as single receptors in MEFs in the absence of any other TAM receptor, and in the retina, Mer activation in wild-type and Tyro3-deficient RPE cells is equivalent. Sixth, in the two settings of PtdSer-dependent ‘homeostatic’ phagocytosis—by RPE cells in the adult retina and Sertoli cells in the adult testes—Mer is the functionally predominant TAM receptor. And seventh, in these settings, Pros1 binding to and activation of Mer alone is sufficient to ensure wild-type levels of phagocytosis.

Prior to this study, the relative binding and selectivity of Gas6 and Pros1 to the individual TAM receptors were incompletely understood. While Gas6 was widely regarded as a universal TAM ligand, the role of Pros1 in TAM-mediated signaling has, until recently, been controversial, and older data regarding the relative potency of Gas6 and Pros1 in the binding and activation of the specific TAM receptors in vitro were conflicting. Perhaps most importantly, all prior analyses of receptor activation following the addition of TAM ligands to cultured cells were confounded by the presence of endogenous TAM receptors in the cell lines used for these analyses. Together with earlier work from our group in the retina, the studies of Figures 7 and 8 represent the only use of molecular genetics to parse differential TAM receptor–ligand signaling interactions in vivo.

A lipid-regulated, calcium-regulated kinase in which the lipid and calcium are both extracellular

Our experiments suggest a model in which the interaction between distinct TAM receptors and ligands defines a signaling signature that is specific for each ligand–receptor pair (Figure 9). This is best illustrated in the case of Gas6 activation of Axl, which is uniquely dependent on Gas6 for activation. Both full-length Gas6 and a Gla-less Gas6 variant that lacks its PtdSer-binding Gla domain bind to Axl with the same sub-nanomolar equilibrium dissociation constant, yet the former is an extremely potent Axl agonist while the latter is inactive, whether assayed in vitro or in vivo. Furthermore, full-length Gas6 cannot activate Axl in the presence of EDTA, which disrupts the binding of the Gas6 Gla domain to PtdSer. In a related study, we have found that just as Axl is uniquely dependent on Gas6 for activation, so is Gas6 uniquely dependent on Axl for its stable localization in several different tissues in vivo. We find that Axl is constitutively pre-bound to Gas6 in these tissues but that this binding does not result in significant Axl activation. Together, all of these observations suggest that the induced exposure of PtdSer is actually the regulated trigger for TAM activation and that the TAM receptor–ligand pair is in reality a PtdSer detector. They also suggest that a crystal structure of the two Ig-like domains of the Axl ectodomain bound to two molecules of Gla-less Gas6 reflects the structure of an inactive complex.

We propose that an effective TAM signaling complex in vivo is always tripartite, in that it is always composed of a TAM receptor, a Gla domain-containing TAM ligand, and the phospholipid PtdSer (Figure 9). This configuration is unique to the TAMs. In this regard, it is important to note that all settings of TAM-dependent ‘homeostatic phagocytosis’ are strictly co-dependent upon the exposure of PtdSer on the surface of the phagocytic target. In the case of RPE cell phagocytosis of juxtaposed PR outer segment tips, PtdSer is locally exposed only on these outer segment tips (i.e., not on the remainder of the photoreceptor) and only during the narrow window after subjective dawn in which phagocytosis occurs each day. The activity of Gla domains is also Ca2+-dependent, as these ions both stabilize the folded structure of the domain and also interact with PtdSer. Thus, the TAM receptor tyrosine kinases represent a novel addition to the set of enzymes, such as protein kinase C, whose activities are regulated by both calcium and lipid binding. The key difference for the TAMs is that neither the lipid nor the calcium binds the kinase directly. Instead, they bind the TAM ligands, which are outside the cell.

Axl–Gas6 and inflammation

The dependence of Axl on Gas6 may be relevant to the fact that all of the very low level of Gas6 that is present in blood appears to be complexed with soluble Axl (sAxl) extracellular domain. Upon Axl activation, this ‘ectodomain’ is proteolytically cleaved from the rest of the receptor, which results in the generation of an sAxl–Gas6 complex. In related work, we have shown that this complex is also generated when Axl is activated in tissues subsequent to the injection of activating (cross-linking) α-Axl antibodies. Although there are conflicting reports as to the presence of soluble Tyro3 and Mer ectodomains in serum and the possibility that Gas6 might also be bound to soluble Mer, antibody depletion of Gas6 from serum does not alter the gel filtration profile of either soluble Mer or Tyro3.

Elevated blood levels of soluble Axl have recently been reported to mark a variety of human disease and trauma states, including aortic aneurysm, lupus flares, pneumonia infection, preeclampsia, coronary bypass, obesity and insulin resistance, and limb ischemia. We suggest that the generation of a soluble Axl–Gas6 complex is triggered by the induced cellular exposure of PtdSer in many of these settings.

Differential TAM activation in human disease

Aberrant TAM signaling in human disease, most notably in cancer, is now a major research focus, and small-molecule TAM tyrosine kinase inhibitors and antibodies that inhibit TAM ligand–receptor binding are in development as cancer therapies. These same inhibitors have been proposed for the treatment of enveloped virus infections. Conversely, TAM activators have been proposed as possible treatments for several autoimmune indications.

In each of these settings, our results indicate that it will be critical to know which TAM receptor to target. This will be particularly important in the context of cancer, since tumors profiled in the TCGA database (https://tcga-data.nci.nih.gov/tcga/) that exhibit mutation or expression changes in the Tyro3, Axl, and Mertk genes display a strong tendency towards mutually exclusive TAM changes across tumor types. At the same time, our studies here, related work in the immune system, and prior analyses all demonstrate that distinct normal functions are preferentially assumed by individual TAM receptors and ligands in macrophages, dendritic cells, Sertoli cells, endothelial cells, and RPE cells. Our delineation of the rules of engagement for TAM signaling (Figure 9) therefore has important implications for the therapeutic application of inhibiting and activating TAM modulators, particularly with respect to their target specificity and the avoidance of possible treatment side effects in the immune, visual, and reproductive systems.

Antibodies and reagents

Antibodies used were as follows: anti-Tyro3 (Santa Cruz, Dallas, TX, sc-1095, R&D Systems, Minneapolis, MN, AF759), anti-Axl (Santa Cruz sc-1097, R&D Systems AF854), anti-Mer (R&D Systems AF591), anti-HA (Covance, Princeton, NJ, MMS-101P, Roche, Mannheim, Germany 11 867 423 001), anti-Gas6 (R&D Systems AF986), anti-Akt (Cell Signaling, Beverly, MA, 4691), anti-Gapdh (Millipore, Billerica, MA, MAB374), anti-cleaved caspase 3 (Cell Signaling 9661), and anti-phosphotyrosine (Millipore 05–321). Human Pros1 was from Enzyme Research Laboratories, South Bend, IN, and Tet-Express from Clontech, Mountain View, CA.

Mice

Mice were bred and housed in the Salk Institute Animal Facility in a sterile environment under a 12-hr light/dark cycle. All experiments and procedures were conducted according to the guidelines established by the Institutional Animal Care and Use Committee (IACUC). The Tyro3−/−, Axl−/−, and Mertk−/− mutants, the Gas6−/− mutants, and the floxed Pros1 mutants were all as described previously. All mice used in this paper were on a pure C57Bl/6 background, with two exceptions: the Tyro3−/−Axl−/−Mertk−/− (TAM TKO) triple mutant mice of Figure 8—figure supplement 1A and the young/old comparison of Figure 8—figure supplement 1B,D, both of which were on a mixed C57Bl/6 × 129sv background.

Generation of cell lines

Spontaneously immortalized MEF cell lines from Tyro3−/−Axl−/−Mertk−/− and Tyro3−/−Mertk−/− mutant mice were generated following a standard 3T3 protocol. Briefly, E13.5–15.5 embryos were isolated from a pregnant female of each genotype, and embryo body was subject to manual dissociation and incubation with trypsin to isolate single cells. Proliferation of isolated cells was monitored for 15–25 passages, and a growth curve was calculated for each cell passage. Immortalized MEFs were subsequently frozen and utilized for experiments.

C-terminal HA-tagged Tyro3 or Axl cDNA was sub-cloned into pMX IRES retroviral vector. Retrovirus was produced in Phoenix Ampho cell lines and used to transduce TAM TKO cells. For Tet-inducible Mer cell lines, C-terminal HA-tagged Mertk cDNA was sub-cloned into a pRetroX-Tre3G vector and co-transfected with pAmpho env expression vector into a GP2-293 cell for retrovirus production according the manufacturer's protocol (Clontech). Clonal populations were generated following antibiotic selection and receptor levels normalized by quantitative immunoblotting using the HA tag.

Generation and purification of recombinant TAM ligands

cDNAs encoding either full-length mouse Gas6/Pros1 or Gas6/Pros1 lacking the Gla domain were sub-cloned into pCep4 vector (Invitrogen, Carlsbad, CA). PCR primers introduced a C-terminal His6 tag for purification and the constructs were transfected into HEK293 cells. Cells were grown to confluency in DMEM supplemented with 10% FBS, 0.25 mg/ml G418, 100 µg/ml hygromycin, and Pen/Strep and subsequently switched to serum-free Pro CDMa medium (Lonza, Walkersville, MD) supplemented with 10 µM vitamin K2 (Sigma, St. Louis, MO) and Pen/Strep for 72 hr. Conditioned medium was passed through a 0.22 µm filter, affinity purified through a nickel-NTA resin, and further purified on an anion exchange column (Mono Q 5/5; GE Healthcare, Pittsburgh, PA) in 20 mM Tris–HCl, pH 8.0 using a sodium chloride gradient.

125I-rmGas6 binding assays

Recombinant full-length mouse Gas6 was 125I-labeled by the iodogen method according to the manufacturer's protocol (Pierce, Rockford, IL). Immortalized Tyro3−/−Mer−/− MEFs were plated in a 12-well dish in triplicate and subsequently pre-starved in 3% FBS in DMEM overnight until cells reach confluency. Cells were placed in starvation medium for 3 hr before binding assays were performed. For binding experiments, cells were incubated with 125I-labeled full-length rmGas6 with increasing concentrations of either unlabeled full-length rmGas6 or unlabeled Gla-less Gas6 for 3 hr on ice. Cells were washed and subsequently lysed overnight in 0.5 M NaOH. Radioactive content of the cell lysates was counted in Opti-Fluor (Perkin Elmer, Waltham, MA) using a scintillation counter (Beckman Coulter, Brea, CA, LS6500). The half-life of the displacement curves was determined by fitting the curve with Prism software (Graphpad).

Immunocytochemistry

Cells were plated on glass coverslips, pre-starved overnight in 3% FBS/DMEM, and subsequently incubated in serum-free medium for 3 hr prior to treatment. Coverslips were briefly washed with 1× PBS, fixed for 15 min with 4% paraformaldehyde (PFA)/PBS, incubated in blocking buffer (3% BSA/0.05% saponin/PBS), primary antibody, and fluorophore-conjugated secondary antibody diluted in blocking buffer. For live labeling for surface receptor expression (Figure 1B and Figure 6—figure supplement 1), coverslips were transferred to chilled serum-free cell culture medium supplemented with anti-Tyro3 or anti-Axl antibodies (R&D Systems) on ice for 30 min. Coverslips were briefly washed with ice cold PBS, fixed for 15 min in 4% PFA/PBS, incubated with a fluorophore-conjugated secondary antibody, and counterstained with Hoechst solution. For live labeling for Gas6 binding assays (Figure 4D), coverslips were transferred to chilled serum-free cell culture medium with and without TAM ligand or EDTA, respectively, at 4°C for 90 min. Coverslips were briefly washed with ice cold PBS, fixed for 15 min in 4% PFA/PBS, and incubated with primary antibody, fluorophore-conjugated secondary antibody, and counterstained with Hoechst solution. Following washing with 0.1% Tween-20/PBS, coverslips were mounted using Fluoromount G (Electron Microscopy Sciences) and visualized with a Zeiss LSM 710 Laser Scanning Confocal Microscope.

Tissue culture, immunoprecipitation, and western blotting

MEFs were grown in Dulbecco's Modified Eagle's Medium supplemented with 10% FBS, and Pen/Strep, and selection antibiotic. Prior to stimulation with ligand, cells were pre-starved overnight in DMEM supplemented with 3% FBS and Pen/Strep and subsequently incubated in starvation conditions for 3 hr.

For BMDM cultures, bone marrow was isolated from tibiae and femurs of 6- to 12-week old C57Bl/6 mice according to the guidelines of the International Animal Care and Use Committee (IACUC). Bones were flushed with DMEM supplemented with 10% FBS and Pen/Strep, spun down at 350 × g for 6 min, incubated with ACK lysis buffer for 1 min, and hematopoietic progenitors incubated with DMEM supplemented with 10% FBS, 30% L929 conditioned medium, Pen/Strep, and glutamax. Cells were supplemented with fresh medium on day 3 and cells re-plated on day 7 in DMEM supplemented with 10% FBS and Pen/Strep for experiments. For activation assays, cells were placed under starvation conditions supplemented with 100 nM dexamethasone and Pen/Strep overnight.

Following stimulation with TAM ligands at the indicated concentrations and time periods, cells were washed in PBS and lysed in lysis buffer [50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 25 mM NaF, 10 µM ZnCl2, and protease and phosphatase inhibitors (Roche, Sigma)] for 30 min on ice. For immunoprecipitation, cell lysates were incubated with anti-HA high affinity (Roche), anti-Mer (R&D System), or anti-Tyro3 (Santa Cruz) antibodies, and either protein A/protein G-Sepharose conjugated beads (Life Technologies). Immunoprecipitates were washed 4× with HNTG buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% Triton X, 10% glycerol, 1 mM Na3VO4), separated by SDS-PAGE, transferred to PVDF membrane (Millipore), incubated with primary antibodies in blocking buffer (1% casein block in PBS) (Biorad), and western blots were developed using an Odyssey Gel Imaging System (Licor).

Histology and immunohistochemistry

Mice were collected at 12–14 weeks and were anesthetized with 2.5% avertin in saline. Mice were perfused with 20 U/ml heparin/PBS and subsequently with 4% PFA in PBS. Eyes were processed as previously described. Testes were collected, immersion fixed overnight at 4°C, infiltrated with 30% sucrose/PBS overnight at 4°C, and flash frozen in TBS tissue freezing medium. 10 µm serial sections were cut for light microscopy studies and immunohistochemistry, respectively. Sections were air dried overnight at room temperature and subsequently frozen at −80°C.

For cCasp3 staining, sections were washed in PBS, incubated in 0.3% H2O2 in PBS to block endogenous peroxidase activity, blocked in 3% BSA in PBS, and incubated in anti-cCasp3 (Cell Signaling) diluted in blocking buffer. DAB staining was performed with an ABC Vectastain Kit (Vector Labs) and Peroxidase Substrate Staining Kit (Vector Labs). Following washing steps in PBS + 0.1% Tween-20, slides were counterstained with hematoxylin for 1 min and mounted using VectaMount (Vector Labs). For quantitation, cCasp3-positive cells and tubule numbers from four testis cross-sections per animal were counted and averaged per animal. Error bars represent standard error of the mean from three independent animals.

Flow cytometry

Cells were plated in 6-cm dishes and when cells reached confluency, they were pre-starved in 3% FBS/DMEM overnight and then incubated in starvation medium for 3 hr before experiment. Supernatant was collected for analysis, and adherent cells were washed with PBS, incubated with 0.25% trypsin briefly, and collected in FACS buffer (0.5% BSA/0.1% Na azide/PBS supplemented with either 2 mM CaCl2 or 10 mM EDTA). Supernatant and cell samples were incubated with pSiva-IANBD and Propidium iodide (PI) (Imgenex) for 30 min on ice. Samples were sorted on a Becton-Dickinson LSR II (Salk Institute Flow Cytometry Core Facility) and data analyzed using FloJo software (Treestar).

Gas6 injections in vivo

Male and female 13- to 15-week old mice were injected intravenously (retro-orbital injection, 100 μl final volume) with 30 μg full-length recombinant mouse Gas6 (in saline), Gla-less recombinant Gas6, or saline as a control. Mice were sacrificed at 30 min post-injection and the spleens split in half: one half was snap frozen for biochemical analysis and the second half was fresh frozen in OCT freezing medium, as indicated in Figure 5.

References 87

  1. 1.

    Anderson HA Maylock CA Williams JA Paweletz CP Shu H Shacter E. 2003. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nature Immunology4:87–91

    Not in our library10.1038/ni871

  2. 2.

    Angelillo-Scherrer A de Frutos P Aparicio C Melis E Savi P Lupu F Arnout J Dewerchin M Hoylaerts M Herbert J Collen D Dahlbäck B Carmeliet P. 2001. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nature Medicine7:215–221

    Not in our library10.1038/84667

  3. 3.

    Avilla E Guarino V Visciano C Liotti F Svelto M Krishnamoorthy G Franco R Melillo RM. 2011. Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Research71:1792–1804

    Not in our library10.1158/0008-5472.can-10-2186

  4. 4.

    Bandyopadhyay PK. 2008. Vitamin K-dependent gamma-glutamylcarboxylation: an ancient posttranslational modification. Vitamins and Hormones78:157–184

    Not in our library10.1016/s0083-6729(07)00008-8

  5. 5.

    Bhattacharyya S Zagorska A Lew ED Shrestha B Rothlin CV Naughton J Diamond MS Lemke G Young JA. 2013. Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host & Microbe14:136–147

    Not in our library10.1016/j.chom.2013.07.005

  6. 6.

    Brandao L Migdall-Wilson J Eisenman K Graham DK. 2011. TAM receptors in leukemia: expression, signaling, and therapeutic implications. Critical Reviews in Oncogenesis16:47–63

    Not in our library10.1615/critrevoncog.v16.i1-2.60

  7. 7.

    Burstyn-Cohen T Heeb MJ Lemke G. 2009. Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. The Journal of Clinical Investigation119:2942–2953

    Not in our library10.1172/jci39325

  8. 8.

    Burstyn-Cohen T Lew ED Traves PG Burrola PG Hash JC Lemke G. 2012. Genetic dissection of TAM receptor-ligand interaction in retinal pigment epithelial cell phagocytosis. Neuron76:1123–1132

    Not in our library10.1016/j.neuron.2012.10.015

  9. 9.

    Carrera Silva EA Chan PY Joannas L Errasti AE Gagliani N Bosurgi L Jabbour M Perry A Smith-Chakmakova F Mucida D Cheroutre H Burstyn-Cohen T Leighton JA Lemke G Ghosh S Rothlin CV. 2013. T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response. Immunity39:160–170

    Not in our library10.1016/j.immuni.2013.06.010

  10. 10.

    Chen J Carey K Godowski PJ. 1997. Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene14:2033–2039

    Not in our library10.1038/sj.onc.1201039

  11. 11.

    Chen Y Wang H Qi N Wu H Xiong W Ma J Lu Q Han D. 2009. Functions of TAM RTKs in regulating spermatogenesis and male fertility in mice. Reproduction138:655–666

    Not in our library10.1530/rep-09-0101

  12. 12.

    Costa M Bellosta P Basilico C. 1996. Cleavage and release of a soluble form of the receptor tyrosine kinase ARK in vitro and in vivo. Journal of Cellular Physiology168:737–744

    Not in our library10.1002/(sici)1097-4652(199609)168:33.0.co;2-u

  13. 13.

    Cummings CT Deryckere D Earp HS Graham DK. 2013. Molecular pathways: MERTK signaling in cancer. Clinical Cancer Research19:5275–5280

    Not in our library10.1158/1078-0432.ccr-12-1451

  14. 14.

    D'Cruz PM Yasumura D Weir J Matthes MT Abderrahim H LaVail MM Vollrath D. 2000. Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat. Human Molecular Genetics9:645–651

    Not in our library10.1093/hmg/9.4.645

  15. 15.

    Demarest SJ Gardner J Vendel MC Ailor E Szak S Huang F Doern A Tan X Yang W Grueneberg DA Richards EJ Endege WO Harlow E Koopman LA. 2013. Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell lines. Biochemistry52:3102–3118

    Not in our library10.1021/bi301588c

  16. 16.

    Duncan HJ LaVail MM Yasumura D Matthes MT Yang H Trautmann N Chappelow AV Feng W Earp HS Matsushima GK Vollrath D. 2003. An RCS-like retinal dystrophy phenotype in mer knockout mice. Investigative Ophthalmology & Visual Science44:826–838

    Not in our library10.1167/iovs.02-0438

  17. 17.

    Ekman C Gottsater A Lindblad B Dahlback B. 2010a. Plasma concentrations of Gas6 and soluble Axl correlate with disease and predict mortality in patients with critical limb ischemia. Clinical Biochemistry43:873–876

    Not in our library10.1016/j.clinbiochem.2010.04.006

  18. 18.

    Ekman C Site DF Gottsater A Lindblad B Dahlback B. 2010b. Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl as markers of large abdominal aortic aneurysms. Clinical Biochemistry43:110–114

    Not in our library10.1016/j.clinbiochem.2009.07.025

  19. 19.

    Ekman C Stenhoff J Dahlback B. 2010c. Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood. Journal of Thrombosis and Haemostasis8:838–844

    Not in our library10.1111/j.1538-7836.2010.03752.x

  20. 20.

    Freedman SJ Furie BC Furie B Baleja JD. 1995. Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX. Biochemistry34:12126–12137

    Not in our library10.1021/bi00038a005

  21. 21.

    Gal A Li Y Thompson DA Weir J Orth U Jacobson SG Apfelstedt-Sylla E Vollrath D. 2000. Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nature Genetics26:270–271

    Not in our library10.1038/81555

  22. 22.

    Godowski PJ Mark MR Chen J Sadick MD Raab H Hammonds RG. 1995. Reevaluation of the roles of protein S and Gas6 as ligands for the receptor tyrosine kinase Rse/Tyro 3. Cell82:355–358

    Not in our library10.1016/0092-8674(95)90424-7

  23. 23.

    Hafizi S Dahlback B. 2006. Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. The FEBS Journal273:5231–5244

    Not in our library10.1111/j.1742-4658.2006.05529.x

  24. 24.

    Holland SJ Pan A Franci C Hu Y Chang B Li W Duan M Torneros A Yu J Heckrodt TJ Zhang J Ding P Apatira A Chua J Brandt R Pine P Goff D Singh R Payan DG Hitoshi Y. 2010. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Research70:1544–1554

    Not in our library10.1158/0008-5472.can-09-2997

  25. 25.

    Hong CC Lay JD Huang JS Cheng AL Tang JL Lin MT Lai GM Chuang SE. 2008. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Letters268:314–324

    Not in our library10.1016/j.canlet.2008.04.017

  26. 26.

    Hsiao FC Lin YF Hsieh PS Chu NF Shieh YS Hsieh CH Lee CH Hung YJ. 2013. Circulating growth arrest-specific 6 protein is associated with adiposity, systemic inflammation, and insulin resistance among overweight and obese adolescents. The Journal of Clinical Endocrinology and Metabolism98:E267–E274

    Not in our library10.1210/jc.2012-3179

  27. 27.

    Huang M Rigby AC Morelli X Grant MA Huang G Furie B Seaton B Furie BC. 2003. Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. Nature Structural Biology10:751–756

    Not in our library10.1038/nsb971

  28. 28.

    Huang X Finerty P Jnr Walker JR Butler-Cole C Vedadi M Schapira M Parker SA Turk BE Thompson DA Dhe-Paganon S. 2009. Structural insights into the inhibited states of the Mer receptor tyrosine kinase. Journal of Structural Biology165:88–96

    Not in our library10.1016/j.jsb.2008.10.003

  29. 29.

    Ishimoto Y Ohashi K Mizuno K Nakano T. 2000. Promotion of the uptake of PS liposomes and apoptotic cells by a product of growth arrest-specific gene, gas6. Journal of Biochemistry127:411–417

    Not in our library10.1093/oxfordjournals.jbchem.a022622

  30. 30.

    Kim YE Chen J Chan JR Langen R. 2010. Engineering a polarity-sensitive biosensor for time-lapse imaging of apoptotic processes and degeneration. Nature Methods7:67–73

    Not in our library10.1038/nmeth.1405

  31. 31.

    Ko CP Yu YL Hsiao PC Yang SF Yeh CB. 2014. Plasma levels of soluble Axl correlate with severity of community-acquired pneumonia. Molecular Medicine Reports9:1400–1404

    Not in our library10.3892/mmr.2014.1933

  32. 32.

    Lacroix R Dignat-George F. 2012. Microparticles as a circulating source of procoagulant and fibrinolytic activities in the circulation. Thrombosis Research129(Suppl 2):S27–S29

    Not in our library10.1016/j.thromres.2012.02.025

  33. 33.

    Leconet W Larbouret C Chardes T Thomas G Neiveyans M Busson M Jarlier M Radosevic-Robin N Pugniere M Bernex F Penault-Llorca F Pasquet JM Pèlegrin A Robert B. 2013. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene

    Not in our library10.1038/onc.2013.487

  34. 34.

    Lee CH Shieh YS Tsai CS Hung YJ Tsai YT Lin CY. 2013. Plasma concentrations predict aortic expression of growth-arrest-specific protein 6 in patients undergoing coronary artery bypass grafting. PLOS ONE8:e79452

    Not in our library10.1371/journal.pone.0079452

  35. 35.

    Lemke G. 2013. Biology of the TAM receptors. Cold Spring Harbor Perspectives in Biology5:a009076

    Not in our library10.1101/cshperspect.a009076

  36. 36.

    Lemke G Burstyn-Cohen T. 2010. TAM receptors and the clearance of apoptotic cells. Annals of the New York Academy of Sciences1209:23–29

    Not in our library10.1111/j.1749-6632.2010.05744.x

  37. 37.

    Lemke G Lu Q. 2003. Macrophage regulation by Tyro 3 family receptors. Current Opinion in Immunology15:31–36

    Not in our library10.1016/s0952-7915(02)00016-x

  38. 38.

    Lemke G Rothlin CV. 2008. Immunobiology of the TAM receptors. Nature Reviews Immunology8:327–336

    Not in our library10.1038/nri2303

  39. 39.

    Lemmon MA. 2008. Membrane recognition by phospholipid-binding domains. Nature Reviews Molecular Cell Biology9:99–111

    Not in our library10.1038/nrm2328

  40. 40.

    Leonard TA Hurley JH. 2011. Regulation of protein kinases by lipids. Current Opinion in Structural Biology21:785–791

    Not in our library10.1016/j.sbi.2011.07.006

  41. 41.

    Liu X Gong Y Jia J Bai Y Gui S Wang T Zhou R. 2014. Plasma concentrations of sAxl are associated with severe preeclampsia. Clinical Biochemistry47:173–176

    Not in our library10.1016/j.clinbiochem.2013.11.001

  42. 42.

    Lu Q Gore M Zhang Q Camenisch T Boast S Casagranda F Lai C Skinner MK Klein R Matsushima GK Earp HS Goff SP Lemke G. 1999. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature398:723–728

    Not in our library10.1038/19554

  43. 43.

    Lu Q Lemke G. 2001. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science293:306–311

    Not in our library10.1126/science.1061663

  44. 44.

    Mackay DS Henderson RH Sergouniotis PI Li Z Moradi P Holder GE Waseem N Bhattacharya SS Aldahmesh MA Alkuraya FS Meyer B Webster AR Moore AT. 2010. Novel mutations in MERTK associated with childhood onset rod-cone dystrophy. Molecular Vision16:369–377

    Not in our library

  45. 45.

    Mark MR Chen J Hammonds RG Sadick M Godowsk PJ. 1996. Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl. The Journal of Biological Chemistry271:9785–9789

    Not in our library10.1074/jbc.271.16.9785

  46. 46.

    McColl A Bournazos S Franz S Perretti M Morgan BP Haslett C Dransfield I. 2009. Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. The Journal of Immunology183:2167–2175

    Not in our library10.4049/jimmunol.0803503

  47. 47.

    Meertens L Carnec X Perera Lecoin M Ramdasi R Guivel-Benhassine F Lew E Lemke G Schwartz O Amara A. 2012. TIM and TAM receptors mediate dengue virus infection. Cell Host & Microbe12:544–557

    Not in our library10.1016/j.chom.2012.08.009

  48. 48.

    Meyer AS Miller MA Gertler FB Lauffenburger DA. 2013. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Science Signaling6:ra66

    Not in our library10.1126/scisignal.2004155

  49. 49.

    Morizono K Xie Y Olafsen T Lee B Dasgupta A Wu AM Chen IS. 2011. The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host & Microbe9:286–298

    Not in our library10.1016/j.chom.2011.03.012

  50. 50.

    Nagata K Ohashi K Nakano T Arita H Zong C Hanafusa H Mizuno K. 1996. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. The Journal of Biological Chemistry271:30022–30027

    Not in our library10.1074/jbc.271.47.30022

  51. 51.

    Nagata S Hanayama R Kawane K. 2010. Autoimmunity and the clearance of dead cells. Cell140:619–630

    Not in our library10.1016/j.cell.2010.02.014

  52. 52.

    Nakano T Kawamoto K Kishino J Nomura K Higashino K Arita H. 1997. Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. The Biochemical Journal323:387–392

    Not in our library10.1042/bj3230387

  53. 53.

    Nandrot EF Dufour EM. 2010. Mertk in daily retinal phagocytosis: a history in the making. Advances in Experimental Medicine and Biology664:133–140

    Not in our library10.1007/978-1-4419-1399-9_16

  54. 54.

    Nelsestuen GL Shah AM Harvey SB. 2000. Vitamin K-dependent proteins. Vitamins and Hormones58:355–389

    Not in our library10.1016/s0083-6729(00)58031-5

  55. 55.

    O'Bryan JP Fridell YW Koski R Varnum B Liu ET. 1995. The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage. The Journal of Biological Chemistry270:551–557

    Not in our library10.1074/jbc.270.2.551

  56. 56.

    Ohashi K Nagata K Toshima J Nakano T Arita H Tsuda H Suzuki K Mizuno K. 1995. Stimulation of sky receptor tyrosine kinase by the product of growth arrest-specific gene 6. The Journal of Biological Chemistry270:22681–22684

    Not in our library10.1074/jbc.270.39.22681

  57. 57.

    Ostergaard E Duno M Batbayli M Vilhelmsen K Rosenberg T. 2011. A novel MERTK deletion is a common founder mutation in the Faroe Islands and is responsible for a high proportion of retinitis pigmentosa cases. Molecular Vision17:1485–1492

    Not in our library

  58. 58.

    Paccez JD Vogelsang M Parker MI Zerbini LF. 2014. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. International Journal of Cancer134:1024–1033

    Not in our library10.1002/ijc.28246

  59. 59.

    Prasad D Rothlin CV Burrola P Burstyn-Cohen T Lu Q Garcia de Frutos P Lemke G. 2006. TAM receptor function in the retinal pigment epithelium. Molecular and Cellular Neurosciences33:96–108

    Not in our library10.1016/j.mcn.2006.06.011

  60. 60.

    Rajotte I Hasanbasic I Blostein M. 2008. Gas6-mediated signaling is dependent on the engagement of its gamma-carboxyglutamic acid domain with phosphatidylserine. Biochemical and Biophysical Research Communications376:70–73

    Not in our library10.1016/j.bbrc.2008.08.083

  61. 61.

    Rothlin CV Ghosh S Zuniga EI Oldstone MB Lemke G. 2007. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell131:1124–1136

    Not in our library10.1016/j.cell.2007.10.034

  62. 62.

    Rothlin CV Lemke G. 2010. TAM receptor signaling and autoimmune disease. Current Opinion in Immunology22:740–746

    Not in our library10.1016/j.coi.2010.10.001

  63. 63.

    Ruggiero L Connor MP Chen J Langen R Finnemann SC. 2012. Diurnal, localized exposure of phosphatidylserine by rod outer segment tips in wild-type but not Itgb5-/- or Mfge8-/- mouse retina. Proceedings of the National Academy of Sciences of USA109:8145–8148

    Not in our library10.1073/pnas.1121101109

  64. 64.

    Sasaki T Knyazev PG Cheburkin Y Gohring W Tisi D Ullrich A Timpl R Hohenester E. 2002. Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. Receptor tyrosine kinase activation by laminin G-like domains. The Journal of Biological Chemistry277:44164–44170

    Not in our library10.1074/jbc.m207340200

  65. 65.

    Sasaki T Knyazev PG Clout NJ Cheburkin Y Gohring W Ullrich A Timpl R Hohenester E. 2006. Structural basis for Gas6-Axl signalling. The EMBO Journal25:80–87

    Not in our library10.1038/sj.emboj.7600912

  66. 66.

    Sather S Kenyon KD Lefkowitz JB Liang X Varnum BC Henson PM Graham DK. 2007. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood109:1026–1033

    Not in our library10.1182/blood-2006-05-021634

  67. 67.

    Schlegel J Sambade MJ Sather S Moschos SJ Tan AC Winges A DeRyckere D Carson CC Trembath DG Tentler JJ Eckhardt SG Kuan PF Hamilton RL Duncan LM Miller CR Nikolaishvili-Feinberg N Midkiff BR Liu J Zhang W Yang C Wang X Frye SV Earp HS Shields JM Graham DK. 2013. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. The Journal of Clinical Investigation123:2257–2267

    Not in our library10.1172/jci67816

  68. 68.

    Scott RS McMahon EJ Pop SM Reap EA Caricchio R Cohen PL Earp HS Matsushima GK. 2001. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature411:207–211

    Not in our library10.1038/35075603

  69. 69.

    Seitz HM Camenisch TD Lemke G Earp HS Matsushima GK. 2007. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. The Journal of Immunology178:5635–5642

    Not in our library10.4049/jimmunol.178.9.5635

  70. 70.

    Shibata T Habiel DM Coelho AL Kunkel SL Lukacs NW Hogaboam CM. 2014. Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthma. The Journal of Immunology192:3569–3581

    Not in our library10.4049/jimmunol.1302766

  71. 71.

    Shimojima M Takada A Ebihara H Neumann G Fujioka K Irimura T Jones S Feldmann H Kawaoka Y. 2006. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. Journal of Virology80:10109–10116

    Not in our library10.1128/jvi.01157-06

  72. 72.

    Shiratsuchi A Umeda M Ohba Y Nakanishi Y. 1997. Recognition of phosphatidylserine on the surface of apoptotic spermatogenic cells and subsequent phagocytosis by Sertoli cells of the rat. The Journal of Biological Chemistry272:2354–2358

    Not in our library10.1074/jbc.272.4.2354

  73. 73.

    Stafford DW. 2005. The vitamin K cycle. Journal of Thrombosis and Haemostasis3:1873–1878

    Not in our library10.1111/j.1538-7836.2005.01419.x

  74. 74.

    Stitt TN Conn G Gore M Lai C Bruno J Radziejewski C Mattsson K Fisher J Gies DR Jones PF Masiakowski P Ryan TE Tobkes NJ Chen DH DiStefano PS Long GL Basilico C Goldfarb M Lemke G Glass D Yancopoulos GD. 1995. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell80:661–670

    Not in our library10.1016/0092-8674(95)90520-0

  75. 75.

    Strauss O. 2005. The retinal pigment epithelium in visual function. Physiological Reviews85:845–881

    Not in our library10.1152/physrev.00021.2004

  76. 76.

    Tanabe K Nagata K Ohashi K Nakano T Arita H Mizuno K. 1997. Roles of gamma-carboxylation and a sex hormone-binding globulin-like domain in receptor-binding and in biological activities of Gas6. FEBS Letters408:306–310

    Not in our library10.1016/s0014-5793(97)00448-1

  77. 77.

    Tsou WI Nguyen KQ Calarese DA Garforth SJ Antes AL Smirnov SV Almo SC Birge RB Kotenko SV. 2014. Receptor tyrosine kinases, TYRO3, AXL and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation. The Journal of Biological Chemistry289:25750–25763

    Not in our library10.1074/jbc.m114.569020

  78. 78.

    Uehara H Shacter E. 2008. Auto-oxidation and oligomerization of protein S on the apoptotic cell surface is required for Mer tyrosine kinase-mediated phagocytosis of apoptotic cells. The Journal of Immunology180:2522–2530

    Not in our library10.4049/jimmunol.180.4.2522

  79. 79.

    van den Brand BT Abdollahi-Roodsaz S Vermeij EA Bennink MB Arntz OJ Rothlin CV van den Berg WB van de Loo FA. 2013. Therapeutic efficacy of Tyro3, Axl, and Mer tyrosine kinase agonists in collagen-induced arthritis. Arthritis and Rheumatism65:671–680

    Not in our library10.1002/art.37786

  80. 80.

    van Meer G Voelker DR Feigenson GW. 2008. Membrane lipids: where they are and how they behave. Nature Reviews Molecular Cell Biology9:112–124

    Not in our library10.1038/nrm2330

  81. 81.

    Varnum BC Young C Elliott G Garcia A Bartley TD Fridell YW Hunt RW Trail G Clogston C Toso RJ Yanagihara D Bennett L Sylber M Merewether LA Tseng A Escobar E Liu ET Yamane HK. 1995. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature373:623–626

    Not in our library10.1038/373623a0

  82. 82.

    Wilhelm I Nagyoszi P Farkas AE Couraud PO Romero IA Weksler B Fazakas C Dung NT Bottka S Bauer H Bauer HC Krizbai IA. 2008. Hyperosmotic stress induces Axl activation and cleavage in cerebral endothelial cells. Journal of Neurochemistry107:116–126

    Not in our library10.1111/j.1471-4159.2008.05590.x

  83. 83.

    Xu J. 2005. Preparation, culture, and immortalization of mouse embryonic fibroblasts. Current Protocols in Molecular BiologyChapter 28:Unit 28.1

    Not in our library10.1002/0471142727.mb2801s70

  84. 84.

    Ye X Li Y Stawicki S Couto S Eastham-Anderson J Kallop D Weimer R Wu Y Pei L. 2010. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene29:5254–5264

    Not in our library10.1038/onc.2010.268

  85. 85.

    Zagórska A Través PG Lew ED Dransfield I Lemke G. 2014. Diversification of TAM receptor tyrosine kinase function. Nature Immunology15:920–928

    Not in our library10.1038/ni.2986

  86. 86.

    Zhang Z Lee JC Lin L Olivas V Au V LaFramboise T Abdel-Rahman M Wang X Levine AD Rho JK Choi YJ Choi CM Kim SW Jang SJ Park YS Kim WS Lee DH Lee JS Miller VA Arcila M Ladanyi M Moonsamy P Sawyers C Boggon TJ Ma PC Costa C Taron M Rosell R Halmos B Bivona TG. 2012. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genetics44:852–860

    Not in our library10.1038/ng.2330

  87. 87.

    Zhu H Sun X Zhu L Hu F Shi L Fan C Li Z Su Y. 2014. Different expression patterns and clinical significance of mAxl and sAxl in systemic lupus erythematosus. Lupus23:624–634

    Not in our library10.1177/0961203314520839

Cited by papers we hold 5

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.